Table 1 Clinical characteristics, laboratory data, and imaging results at ICU admission
Characteristic | Measurement |
|---|---|
Age, median (IQR), years | 68 (60–69) |
Male, no. (%) | 10 (91%) |
Body weight, median (IQR), kg | 71 (69–82) |
Number of patients with coexisting disorders, no. (%) | |
 Asthma | 0 (0%) |
 Cancer | 1 (9%) |
 Chronic kidney disease | 0 (0%) |
 Chronic obstructive pulmonary disease | 1 (9%) |
 Diabetes mellitus | 3 (27%) |
 Hypertension | 4 (36%) |
Duration of symptoms before admission, median (IQR), days | 8 (7–11) |
Number of patients with symptoms, no. (%) | |
 Fever | 9 (82%) |
 Cough | 5 (45%) |
 Shortness of breath | 8 (73%) |
Laboratory data | |
 White blood cell count, median (IQR), per mm3 | 6900 (5800–10,850) |
 Lymphocyte count, median (IQR), per mm3 | 851 (759–1164) |
 Hemoglobin, median (IQR), g/dl | 15.0 (13.5–16.3) |
 Platelet count, median (IQR), per mm3 | 19.6 (18.6–26.4) |
 Lactate dehydrogenase level, median (IQR), U/l | 518 (417–752) |
 Aspartate aminotransferase level, median (IQR), U/l | 54 (49–90) |
 Alanine aminotransferase level, median (IQR), U/l | 47 (35–58) |
 Serum creatinine level, median (IQR), mg/dl | 0.85 (0.70–1.03) |
 Creatinine kinase level, median (IQR), U/l | 213 (129–579) |
 Prothrombin time, median (IQR), international normalized ratio | 1.08 (1.03–1.13) |
 Activated partial thromboplastin time, median (IQR), s | 28.8 (28.4–32.1) |
d-dimer level, median (IQR), μg/dl | 1.4 (1.1–11.8) |
 PaO2/FiO2 ratio, median (IQR) | 131 (114–198) |
 SOFA score, median (IQR) | 3.0 (2.5–4.5) |
 APACHE II score, median (IQR) | 14.0 (12.0–15.5) |
Computed tomography findings | |
 Patients with consolidation, no. (%) | 6 (55%) |
 Patients with ground-glass opacities, no. (%) | 10 (91%) |
 Patients with pulmonary infiltration, no. (%) | 2 (18%) |